Abstrakts und Beiträge

Sittenthaler C., Cauza E., Hanusch – Enserer U., Frischmuth K., Fabian B., Dunky A. . Short-term infliximab therapy improves symptoms of psoriatic arthrits and decreases concentrations of cartilage oligometric matrix protein. Hungarian Rheumatology 2004 Suppl. A 19 

Sittenthaler C., Thun M., Haber P., Dunky A., Cauza E., Auswirkungen von verschiedenen Trainingsformen auf den Blutzuckerstoffwechsel bei Diabetes mellitus 2 Patienten unter Verwendung eines permanenten Glukose Monitoring Systems Acta Med. Austriaca 2005 Suppl (ÖDG 12/2005) 

Sittenthaler C., Haberhauer G., Fasching P. Adult form of familial hypophosphatasia with hypo- and hypermobility of joints, DRhG Hamburg 09/2007  Sittenthaler C., Kurzer Überblick über ausgewählte Highlights vom Deutschen Rheuma Kongress 2007, Universum Innere Medizin 07/07 

Sittenthaler C., Diagnose und Therapie der Adipositas, Ärztekrone 2007

Sittenthaler C., Manifeste Osteoporose, Diagnose und Therapie, Spectrum Osteoporose 02/10

Wissenschaftliche klinische Studien

A 13 – week, multicenter, randomized, double-blind, double-dummy,placebo-controlled, parallel trial of 2 different dose regimens of lumiracoxib in patients with primary knee osteoarthritis, using celecoxib as a comparator CCOX189A2361, June 2003
Phase 3 clinical trial.

Inhaled human insulin with AERxiDMS as prandial monotherapy compared to combination therapy with metformin and glimepirid in type 2 Diabetes: an eighteen week, open label, multicenter, randomised, parallel group trial to investigate efficay and safety NN1998-1787, Nov. 2006
Phase 3a clinical trial.  

Klinische Studie zur Verlaufsbeeinflussung des Gestationsdiabetes durch Substitution des bestehenden Carnitinmangels, Jänner 2007
Phase 4 clinical trial.

Derzeit betreute Studien

1: A multinational, multicenter, post-authorization, prospective observational cohort study to assess the profile of vildagliptin and the fixed-dose combination of vildagliptin/ metformin relative to comparator oral anti-diabetic drugs in patients with type 2 diabetes in a real-world setting.
Pr. Nr.: CLAF237A2403, 2009/2010
Participation in phase 4 clinical trail as Sub-Investigator

2: An Open-Label Study Assessing the Addition of Subcutaneous Golimumab (GLM) to Conventional Disease-Modifying Antirheumatic Durg (DMARD) Therapy in Biologic-Naïve Subjects With Rheumatoid Arthritis (Part 1), Followed by a Randomized Study Assessing the Value of Combined Intravenous and Subcutaneous GLM Administration Aimed at Inducing and Maintaining Remission (Part 2)
Study No. P06129, 2009/2010
Participation in phase 3 clinical trail as Sub-Investigator

3: A Golimumab Phase 3b, Multicenter, Switch Assessment Of Subcutaneous And Intravenous Efficacy In Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment with Etanercept (Enbrel) Or Adalimumab (Humira) 2009/2010
CNTO148ART3002
Participation in phase 3 clincial trail as Sub-Investigator

4: Infliximab as First Line Therapy in Patients with Early Active Axial Spondyloarthritis Trial (INFAST) P05336, 2009/2010
Participation in phase 3 clinical trail as Sub-Investigator

5: Etoricoxib in Patients with Rheumatoid Arthritis
Study No. MK-0663-017, 2009/2010
Participation in phase 3 clinical trail as Sub-Investigator

6: Etoricoxib in Patients with Ankylosing Spondylitis
MK-0663-018, 2009/2010
Participation in phase 3 clinical trail as Sub-Investigator

7: Adherence to PTH (1-84) treatment in Europe. A non-interventional cohort study collecting safety information and examining reasons and predictors for adherence to PTH (1-84) treatment in Usual Clinical Settings
Study No. FP-002-IM, 2009/2010
Participation in phase 4 clinical trail as Sub-Investigator